Sarah Moore
Director, Pre-Approval Access Strategy, Oncology ImmunoGen
Seminars
Thursday 26th March 2026
Panel Discussion: Planning & Executing Smooth Transitions from EAP to Commercial Supply
8:30 am
- Anticipating patient needs and country-specific timelines to maintain uninterrupted access during program closure or handover
- Aligning internal teams, local stakeholders, and advocacy groups to address operational, regulatory, and financial challenges
- Learning from real-world multi-country cases to optimize transition planning and avoid common pitfalls
Thursday 26th March 2026
Bridging the Gap Between Regulatory Approval & Commercial Launch: Access Strategies
9:00 am
- What are the important characteristics of early access in Europe, including what makes it complicated and whether it could become easier
- What are the key practical perspectives of EU early access to be aware of, particularly after centralized Marketing Authorization
- What does EU early access look like in small biotech, and how can the transition of an early access program from biotech to pharma be supported
